Cellular and T cell engager Immunotherapy
Phase Ib Study Investigating the Safety, Pharmacokinetics, and Efficacy of Subcutaneous Administration of ABBV-383 in Patients With Relapsed/Refractory Multiple Myeloma
Hila Magen, MD (she/her/hers)
Head of Multiple Myeloma Unit
Chaim Sheba Medical Center, Ramat-Gan, Sackler Faculty of Medicine, Tel Aviv University, Israel, United States